The intravenous solutions market was valued at USD 18.1 billion in 2025. Grand View Research projects it will reach USD 28.7 billion by 2033, a CAGR of 5.8% from 2026 to 2033. The 2026 estimate is USD 19.3 billion. North America led with a 41.8% revenue share in 2025, and the U.S. was the largest country market.
Market Overview: Why Demand for IV Fluids Keeps Rising
Intravenous (IV) solutions supply essential nutrients and are a main source of energy. They are used wherever a patient cannot hydrate or eat normally, including emergency rooms, intensive care units, operating theaters and general wards. The 2025 to 2026 step alone is worth about USD 1.2 billion, or roughly 6.6% growth, which is close to the long-run CAGR. That suggests steady, recurring demand rather than a short-term spike.
Surgical volume is a major growth driver, because IV fluids are used before, during and after procedures to balance fluids and electrolytes, preserve blood volume and deliver anesthetics and antibiotics. The report cites CDC data showing 1,173,391 cesarean deliveries in the U.S. in 2024 (32.4% of all deliveries). It also cites more than 700,000 total knee replacements a year and nearly 3 million cataract surgeries a year. Chronic disease, hospital admissions and an aging population add to the load.
The market also has weak points. Periodic IV fluid shortages, strict sterile-manufacturing rules and catheter-associated infection risk all constrain participants. Production is concentrated among a small number of manufacturers, so one disrupted plant can ripple through hospital supply chains.
Market projections referenced in this article are drawn from Grand View Research. To explore the data further, try their Prism AI tool.
Key Segments: The Biggest Segments Are Not the Fastest-Growing
Looking at how the intravenous solutions market splits shows a pattern. The segments with the most revenue today are not the ones growing fastest.
By product type, crystalloid solutions held 58.0% of revenue in 2025. This group covers normal saline, Lactated Ringer’s, dextrose and balanced crystalloids, which are cheap, versatile and consumed in enormous volumes. Parenteral nutrition (PN) solutions are expected to grow at the fastest CAGR through 2033. The drivers are malnutrition, gastrointestinal disorders, cancer, premature infants who need nutritional support, and the move toward ready-to-use multi-chamber bags.
By sales channel, institutional buyers (hospitals, clinics, ambulatory surgical centers and long-term care facilities) accounted for 75.0% of revenue. Online is the fastest-growing channel at a 7.8% CAGR over 2026 to 2033, helped by digital procurement and home care demand.
By end use, hospitals held 50.8% in 2025, but the home segment is expected to grow fastest. Patients on chemotherapy, long antibiotic courses or hydration therapy often prefer to avoid repeat hospital visits and hospital-acquired infections.
Volume sits in the hospital and crystalloid bag, while momentum is moving toward home delivery, nutrition formulations and online ordering. Suppliers that serve only the traditional hospital channel may find the fastest-growing demand elsewhere.
Download a free sample report or claim your copy of this full market intelligence report
Regional Momentum: North America Leads, Asia Pacific Accelerates
North America’s 41.8% share reflects high chronic disease prevalence, rising surgical activity and a growing geriatric population. Asia Pacific is the fastest-growing region, with a projected CAGR of 9.7% over the forecast period. That is well above the 5.8% global rate, and it is driven by chronic disease, malnutrition and rising healthcare purchasing power.
China shows how demand and profitability can diverge. More than 50 domestic suppliers compete under aggressive government procurement, and in late 2024 Baxter exited China’s commodity IV fluids market because it could no longer serve it profitably. For multinationals, a large patient base does not guarantee a viable market.
Key Industry Players in the Intravenous Solutions Market
Grand View Research profiles twelve companies:
- Fresenius Kabi AG
- B. Braun SE
- Baxter
- Otsuka Pharmaceutical Co., Ltd.
The report treats Fresenius Kabi, B. Braun, Baxter, Otsuka, Pfizer and ICU Medical as established players. They compete on broad portfolios, large-scale sterile manufacturing and entrenched hospital relationships, but face high manufacturing costs and pricing pressure from providers. JW Life Science, Vifor Pharma, Kelun and AdvaCare Pharma are classed as emerging players. They compete on pricing and regional expertise, with less global reach and brand recognition.
Recent moves show where the competition is heading:
- Pediatric nutrition: In June 2026, Fresenius Kabi launched Pedismof in Europe, a ready-to-use three-chamber bag with age-specific pediatric parenteral nutrition formulations.
- Safety technology: In March 2026, Baxter entered an exclusive distribution collaboration with Vigilant Software for the IV Verify Line Labeling System, an automated tool for IV medication labeling accuracy.
- Manufacturing scale: In November 2024, Otsuka Pharmaceutical Factory and ICU Medical formed a joint venture to strengthen North American IV supply, creating a network with estimated annual production of 1.4 billion units.
U.S. Landscape: The Largest Market, With Supply Resilience Under Watch
The U.S. is the largest country market. Disabilities and malnutrition linked to chronic conditions and an aging population are lifting demand for parenteral nutrition products. Cardiovascular disease adds to this, since it raises the prevalence of myocardial ischemia-reperfusion injury, which drives parenteral nutrition use in managing these injuries.
Supply resilience matters as much as demand here. Baxter restored pre-hurricane production at its North Cove, North Carolina, facility in February 2025 after Hurricane Helene disrupted large-volume IV solution output. That recovery improved U.S. availability of essential IV fluids, and it showed how a single plant can affect national supply.
Home infusion is the other U.S. story. In February 2026, KabaFusion announced a growth investment from Nautic Partners to expand home and alternate-site infusion services across the country.
Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs
Outlook
Between now and 2033, the intravenous solutions market looks like a stable hospital-driven base with faster-growing edges. Those edges are parenteral nutrition, home infusion, online procurement and Asia Pacific. Manufacturers that combine reliable large-scale sterile production with ready-to-use formats and home-care access are best placed to capture the USD 28.7 billion opportunity.
